

Contents

CHAPTER 1

Role of the Outer Membrane of Gram-Negative Bacteria in Antimicrobial Resistance

H. NIKAIDO. With 3 Figures	1
A. Introduction	1
B. The Outer Membrane Barrier	1
I. The Lipid Bilayer	1
II. The Porin Pathway	3
III. The Specific Pathways	4
C. The Measurement of Outer Membrane Permeability	4
I. Measurement in Intact Cells	4
II. Measurement in Reconstituted Vesicles	7
D. Permeability of Bacterial Outer Membranes to β -Lactam Antibiotics	9
I. Penetration Rates in <i>E. coli</i>	9
II. Permeation Rate and Efficacy in <i>E. coli</i>	12
III. Outer Membrane Permeability in Other Enteric Bacteria	17
IV. Outer Membrane Permeability in <i>P. aeruginosa</i> and Other “Intrinsically Resistant” Organisms	18
V. Gram-Negative Bacteria with Very High Sensitivity to β -Lactams	20
E. Permeation of Some Other Agents Through Porin Channels	21
F. Contribution of Non-porin Pathways	22
G. Outer Membrane Permeability to Polycationic Agents	24
I. Polymyxin and Related Antibiotics	24
II. Aminoglycosides	25
H. Conclusions	26
References	27

CHAPTER 2

Cytoplasmic Membrane Transport and Antimicrobial Resistance

L. E. BRYAN	35
A. Summary of Transport Systems	35
I. Diffusional	35
II. Active Transport	35
III. Group Translocation	36

B. Antimicrobial Resistance Associated with Antimicrobial Transport . . .	36
I. Introduction	36
II. Use of Existing Transport Systems	36
III. Use of Special Transport Systems	39
IV. Diffusional Systems	50
References	53

CHAPTER 3

Susceptibility and Resistance of *Plasmodium falciparum* to Chloroquine

D. J. KROGSTAD, P. H. SCHLESINGER, and I. Y. GLUZMAN. With 2 Figures . . .	59
A. Introduction	59
I. Magnitude of Malaria as a Medical Problem and the Importance of Antimalarials	59
II. Potential Interventions – Vaccines Vs. Drugs	59
III. The Effect of Parasite Stage	60
IV. Drugs Active Against Asexual Erythrocytic Parasites	60
B. Mechanism of Chloroquine Action	61
I. Previous Theories of Chloroquine Action	61
II. Chloroquine and Acid Vesicles	61
III. Chloroquine as a Weak Base	62
IV. The Effect of Weak Bases on Lysosomal (Intravesicular) pH	62
V. Concentration of Weak Bases Within Acid Vesicles	62
VI. Effects of Mono- and Diprotic Weak Bases on Vesicle pH	63
VII. The “Non-weak Base” Effect	64
VIII. Chloroquine Accumulation by <i>Plasmodium falciparum</i>	66
IX. Potential Biological Consequences of Raising Intravesicular pH	67
C. Mechanism of Chloroquine Resistance	68
D. Action of Mefloquine, Quinine, and Quinidine	70
I. Mechanism of Mefloquine Action	70
II. Quinine and Quinidine as Weak Bases	70
III. Non-weak Base Activity and the Safety of Antimalarials	71
E. Summary of Basic Concepts and Prospects for the Future	71
I. The Acid Vesicle as a Pharmacologic Target Site	71
II. Structure-Activity Relationships	71
III. Prospects for the Future	72
References	72

CHAPTER 4

Resistance to β -Lactam Antibiotics Mediated by Alterations of Penicillin-Binding Proteins

B. G. SPRATT	77
A. Introduction	77
B. Mechanisms of Resistance to β -Lactam Antibiotics	78
C. Classification of PBP Alterations in β -Lactam-Resistant Strains	79
I. Alterations in the Affinities of PBPs for β -Lactam Antibiotics	79

II. Alterations in the Amounts of PBPs	80
III. Resistance by Illegitimate Acquisition of a Resistant PBP	80
IV. Resistance by Homologous Acquisition of a Resistant PBP	80
D. Laboratory Studies on the Development of β -Lactam-Resistant PBPs in <i>E. coli</i>	81
I. Amino Acid Substitutions That Decrease the Affinity of PBP 3 for β -Lactam Antibiotics	81
II. Re-modelling of the Active Centre of PBP 3 to Obtain High Level Resistance to β -Lactam Antibiotics	82
E. PBP Alterations in Clinical Isolates	83
I. <i>Neisseria gonorrhoea</i>	83
II. <i>Neisseria meningitidis</i>	86
III. <i>Haemophilus influenzae</i>	86
IV. <i>Streptococcus pneumoniae</i>	88
V. <i>Staphylococcus aureus</i>	92
VI. Enterococci	96
F. Concluding Remarks	96
References	97

CHAPTER 5

Plasmid-Determined Beta-Lactamases

A. A. MEDEIROS. With 1 Figure	101
A. Introduction	101
B. General Properties of Beta-Lactamases	102
C. Classification of Beta-Lactamases	103
D. Properties of Plasmid-Determined Beta-Lactamases	106
I. Broad-Spectrum Beta-Lactamases	106
II. Oxacillin-Hydrolyzing Beta-Lactamases	108
III. Carbenicillin-Hydrolyzing Beta-Lactamases	108
IV. Amp C Type Beta-Lactamases	109
V. Staphylococcal Beta-Lactamases	109
VI. Streptococcal Beta-Lactamases	110
E. Relatedness of Plasmid-Determined Beta-Lactamases	110
I. Immunological Cross-Reactivity	110
II. DNA Hybridization	111
III. Amino Acid and Nucleotide Sequencing	112
F. Spread of Plasmid-Determined Beta-Lactamases in Patient Flora . .	113
I. Emergence of Variant Beta-Lactamases Active Against Newer Beta-Lactams	118
G. Contribution of Plasmid-Determined Beta-Lactamases to Beta-Lactam Antibiotic Resistance	119
References	120

CHAPTER 6

The Chromosomal Beta-Lactamases

C. C. SANDERS	129
A. Introduction	129
B. General Characteristics	129
I. The Reaction Catalyzed	129
II. Classification Schemes	130
C. Cephalosporinases	132
I. Inducible Cephalosporinases	132
II. Constitutive Cephalosporinases	137
D. Oxyiminocephalosporinases	138
I. Inducible Oxyiminocephalosporinases	138
II. Constitutive Oxyiminocephalosporinases	139
E. Penicillinases	140
F. Broad-Spectrum Beta-Lactamases	141
I. Metalloenzymes	141
II. Enzymes from <i>Klebsiella</i>	141
G. Subclassification Scheme for Chromosomal Beta-Lactamases	144
References	144

CHAPTER 7

Beta-Lactamases: Genetic Control 151

S. CHAMBERLAND	151
A. Introduction	151
B. Classification of Beta-Lactamases	151
C. Regulation of Class A Enzymes	152
I. <i>Bacillus licheniformis</i>	153
II. <i>Staphylococcus aureus</i>	154
D. Regulation of Class C Enzymes	155
I. Constitutive: <i>Escherichia coli</i>	156
II. Inducible	158
E. Conclusion	163
References	163

CHAPTER 8

Resistance to Quinolones and Fluoroquinolones

L. J. V. PIDDOCK. With 3 Figures	169
A. Introduction	169
B. Mechanism of Action	170
I. DNA Gyrase	170
II. SOS Response	172
III. Other Properties of Quinolones	174

C. Mechanisms of Resistance	175
I. Properties of DNA Gyrase Mutants	175
II. Other Genetically Characterised Mutations Conferring Quinolone Resistance	177
III. Properties of Mutants Defective in Components of the SOS Response	179
IV. Properties of Strains of Gram-Negative Bacteria with Phenotypically Characterised Mechanisms of Resistance	179
V. Mechanisms of Resistance in Bacteria Selected In Vivo	180
VI. Inherent Resistance	183
D. Clinical Implications of Resistance Mechanisms	183
I. Pharmacokinetics	183
II. Pathogenicity	186
E. Summary and Conclusions	187
References	187

CHAPTER 9

Ribosomal Changes Resulting in Antimicrobial Resistance

H. HUMMEL and A. BÖCK. With 4 Figures	193
A. Introduction	193
B. Changes in Ribosomal Proteins	194
I. Protein Changes in the Eubacterial Small Ribosomal Subunit	194
II. Protein Changes in the Small Subunit from Eukaryotic Ribosomes	201
III. Protein Changes in the Eubacterial 50S Subunit	201
IV. Protein Changes in the Eukaryotic 60S Subunit	204
C. Changes in Ribosomal RNA Which Result in Antimicrobial Resistance	205
I. RNA Changes in the Small Ribosomal Subunit	205
II. RNA Changes in the Large Ribosomal Subunit	208
D. Antibiotics and Phylogeny	211
E. Ribosomal Antibiotic Resistance in Clinical Isolates	215
F. Conclusions and Perspectives	215
References	216

CHAPTER 10

Methylation of RNA and Resistance to Antibiotics

E. CUNDLIFFE. With 1 Figure	227
A. Introduction	227
B. Resistance Due to Target Site Modification	227
I. Resistance to Aminoglycosides	228
II. Resistance to Thiostrepton	234
III. Resistance to Macrolides, Lincosamides, and Antibiotics Related to Streptogramin B	237
C. Concluding Remarks	244
References	244

CHAPTER 11

Resistance to Trimethoprim

L. P. ELWELL and M. E. FLING. With 10 Figures	249
A. Introduction	249
B. Mechanisms of Resistance	251
I. Thymine-Requiring Strains	251
II. Decreased Permeability	253
III. Mutations in Dihydrofolate Reductase Structural Gene	253
IV. Mutations Affecting Dihydrofolate Reductase Expression	255
V. Trimethoprim Resistance in <i>Staphylococcus aureus</i>	258
VI. Intrinsic Resistance	259
VII. R-Plasmid Resistance in Gram-Negative Organisms	259
C. Epidemiology of Trimethoprim Resistance	271
I. Trimethoprim Resistance in Gram-Negative Organisms	271
II. Trimethoprim Resistance in the Enteric Organisms <i>Shigella</i> and <i>Salmonella</i>	274
III. Trimethoprim Resistance in the Non-enterobacteriaceae	276
IV. Role of Transposition in the Dissemination of Plasmid Dihydrofolate Reductase Genes	277
D. Mechanism and Epidemiology of Trimethoprim Resistance in Gram-Positive Organisms	278
E. Conclusion	280
References	281

CHAPTER 12

Resistance to Sulfonamides

R. L. THEN. With 1 Figure	291
A. Introduction	291
B. Sulfonamide Usage Today	292
I. Sulfonamides Alone and Combined with Antibiotics	292
II. Sulfonamides in Combination with Dihydrofolate Reductase Inhibitors	292
III. Sulfones and Other Agents	294
IV. Sulfonamides in Veterinary Medicine	294
C. Prevalence of Sulfonamide Resistance	295
I. Bacteria	295
II. Protoza	296
D. Mode of Action of Sulfonamides	297
E. Mechanisms of Sulfonamide Resistance	297
I. Bacteria	297
II. Plasmodia	303
F. Genetics of Sulfonamide Resistance	304
References	307

CHAPTER 13

Chloramphenicol Acetyltransferases	
W. V. SHAW and A. G. W. LESLIE. With 5 Figures	313
A. Chloramphenicol Resistance: General Aspects	313
I. Introduction	313
II. Chemistry and Properties of Chloramphenicol	313
III. Emergence of Resistance to Chloramphenicol	314
B. Enzymology of Chloramphenicol-Acetylation	315
I. Acetylation and Inactivation	315
II. Mechanism of the Reaction	316
III. Structure of Chloramphenicol Acetyltransferase	317
IV. Sequence Comparisons and Natural Variation	320
C. Control of Expression of Chloramphenicol Acetyltransferases	320
I. General Considerations	320
II. Gram-Negative Bacteria	321
III. Gram-Positive Bacteria	321
References	322

CHAPTER 14

General Properties of Resistance Plasmids	
D. E. TAYLOR. With 5 Figures	325
A. Introduction	325
B. Plasmid Classification	325
I. Incompatibility Testing	327
II. Extant and Religated Incompatibility Groups in Enterobacteriaceae	328
III. Incompatibility Groups in <i>Pseudomonas aeruginosa</i>	328
IV. Incompatibility Groups in <i>Staphylococcus aureus</i>	329
V. Designation of Incompatibility Subgroups and Complexes	329
C. Structure of Plasmids	333
I. General Structure	333
II. Molecular Sizes of Plasmids	333
III. Plasmid Organization	335
D. Plasmid Transfer	335
I. Conjugative Pili	335
II. Transfer Conditions	337
III. Transfer Gene Organization	338
IV. Surface Exclusion Systems	340
E. Plasmid Maintenance and Replication	341
I. Maintenance of IncH Plasmids	341
II. Replication Functions of Mini-plasmids	342
III. Incompatibility	344
F. Antibiotic Resistance and Other Plasmid-Encoded Properties	346
I. Chloramphenicol Resistance	346
II. Tetracycline Resistance	346

III. Trimethoprim Resistance 347

IV. Tellurium Resistance 347

V. Bacteriophage Inhibition 349

VI. Citrate Utilization 349

VII. Lactose Utilization 349

VIII. Determinants of Pathogenicity 350

G. Conclusions and Directions for Future Studies 350

References 351

CHAPTER 15

Clinical Laboratory Testing for Antimicrobial Resistance

F. D. SCHOENKNECHT. With 1 Figure 359

A. Introduction 359

B. Standardization of Test Procedures 360

 I. Early Efforts 360

 II. Reports, Guidelines, and Standards by the National Committee for Clinical Laboratory Standards 361

III. Culture Media for Antimicrobial Susceptibility Tests 362

IV. Present State of Standardized AST 363

 V. Remaining Problems 364

C. Relevance of Testing and Clinical Laboratory Correlation 364

 I. Influence of the Nature and Design of the Test System 365

 II. Influence of Host Factors 367

 III. Influence of Reporting Methods 369

 IV. Problems with Certain Organisms and Antibiotics 370

D. DNA Probes for AST 374

E. Conclusions 378

References 378

CHAPTER 16

The Molecular Epidemiology of Antimicrobial Resistance

D. M. SHLAES and C. A. CURRIE-MCCUMBER. With 3 Figures 387

A. Introduction 387

B. Plasmids as Strain Markers 388

 I. Brief Review of Methods 388

 II. Plasmids as Strain Markers 389

 III. Molecular Epidemiology in Gram-Positive Cocci 392

C. Epidemic Plasmids 394

D. Endemic Antibiotic Resistance 395

 I. The Spread of Resistant Strains 395

 II. Endemic Resistance Resulting from the Spread of R Plasmids Between Strains 396

 III. The Contribution of Stable R Plasmids to Endemic Resistance 401

 IV. The Role of Antibiotic Usage in the Selection and Dissemination of Antibiotic Resistance 403

References 405

CHAPTER 17

**Microbial Persistence or Phenotypic Adaptation to Antimicrobial Agents:
Cystic Fibrosis as an Illustrative Case**

L. E. BRYAN 411

A. Introduction 411

B. Cystic Fibrosis and Microbial Persistence 412

C. Factors Associated with Persistence of *P. aeruginosa* During
Antimicrobial Therapy in Cystic Fibrosis 413

 I. Host-Related Factors 413

 II. Bacterially Related Factors 415

References 418

CHAPTER 18

Microbes Causing Problems of Antimicrobial Resistance

L. E. BRYAN 421

A. *Staphylococcus* Species 421

B. *Streptococcus* Species 423

 I. *Streptococcus pneumoniae* 423

 II. *Streptococcus pyogenes* 424

 III. *Streptococcus faecalis* 424

 IV. *Haemophilus influenzae* 426

 V. *Neisseria gonorrhoeae* 427

C. Gram-Negative Aerobic Bacilli 428

 I. Gastrointestinal Pathogens 428

 II. Nosocomial Gram-Negative Bacteria 431

 III. Mycobacteria 433

 IV. *Bacteroides* Species 435

 V. *Legionella pneumophila* 436

 VI. Miscellaneous Bacteria 436

References 436

Subject Index 441